Novus Therapeutics to Participate in Two Investor Conferences
Novus Therapeutics, Inc. is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).
Read More
Category: News Release
Novus Therapeutics Reports Third Quarter 2019 Financial Results
The company is making progress with the OP0201 otitis media program.
Read More
Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion
Study C-009 is designed to explore the effect of daily administration of OP0201 in patients with COME, a non-infectious form of otitis media.
Read More
MJ Holdings Releases Audited Financial Statements
The Company’s management is now diligently working on preparing and filing our quarterly financial reports for the first half of 2019.
Read More
Novus Therapeutics to Participate in Two Upcoming Investor Conferences
Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).
Read MoreGET LISTED
